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Scope: Genistein from foods or supplements is metabolized by the gut microbiota and the
human body, thereby releasing many different metabolites into systemic circulation. The order
of their appearance in plasma and the possible influence of food format are still unknown. This
study compared the nutrikinetic profiles of genistein metabolites.
Methods and results: In a randomized cross-over trial, 12 healthy young volunteerswere admin-
istered a single dose of 30mg genistein provided as a genistein tablet, a genistein tablet in low fat
milk, and soy milk containing genistein glycosides. A high mass resolution LC-LTQ-Orbitrap
FTMS platform detected and quantified in human plasma: free genistein, seven of its phase-II
metabolites and 15 gut-derived metabolites. Interestingly, a novel metabolite, genistein-4′-
glucuronide-7-sulfate (G-4′G-7S) was identified. Nutrikinetic analysis using population-based
modeling revealed the order of appearance of five genistein phase II metabolites in plasma:
(1) genistein-4′,7-diglucuronide, (2) genistein-7-sulfate, (3) genistein-4′-sulfate-7-glucuronide,
(4) genistein-4′-glucuronide, and (5) genistein-7-glucuronide, independent of the food matrix.
Conclusion: The conjugated genisteinmetabolites appear in a distinct order in human plasma.
The specific early appearance ofG-4′,7-diG suggests amultistep formation process for themono
and hetero genistein conjugates, involving one or two deglucuronidation steps.
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tration; tpeak, time between first appearance andmaximum inten-
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1 Introduction
Soy isoflavones have been proposed to have protective effects
in a variety of health conditions, including postmenopausal
osteoporosis [1], alleviation of menopause-related hot flashes
[2], risk reduction of certain cancers [3], and cardiovascular
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events [4]. A number of these benefits are attributed to the
phytoestrogen activity of isoflavones such as genistein and
daidzein. In view of these health benefits isoflavones are at-
tractive to be used in dietary supplements. In unprocessed
soybeans or in soy foods, isoflavones are mainly present as
conjugates in the form of glucosides, but also as acetyl- or
malonyl-glycosides.
Only the unconjugated forms of isoflavones are absorbed
by the human body [5]. Interestingly, in unprocessed soy-
beans and some soy products the genistein aglycone is only
found in low concentrations, while its glucoside conjugate,
genistin, is muchmore abundant [6]. Nevertheless, in a num-
ber of soy foods the genistein aglycone is present in elevated
amounts. The glucoside forms of isoflavones in food are hy-
drolyzed in the intestine before crossing the gutmucosa. Sim-
ilar to daidzein that is metabolized by intestinal conversion
to equol, it has recently been proposed that genistein is trans-
formed by the gutmicroflora to 5-hydroxy-equol [7]. However,
only a percentage (25–60%) of soy consumers is able to form
equol out of daidzein. The presence of specialized intestinal
bacteria is needed for the conversion of daidzein into dihydro-
daidzein to formequol [8]. Analogously, it has beenpostulated
that genistein is metabolized via dihydrogenistein to form
5-hydroxy-equol, when 5-hydroxy-equol producing bacteria
copopulate the gut, but so far this has only been demonstrated
inmice, not in humans [7,9]. In the nineties, different groups
have explored the catabolic pathway of genistein [10–13].
They proposed a metabolic genistein biotransformation by
the gut microbiota that goes through the catabolic metabo-
lites dihydrogenistein, 6′-hydroxy-O-desmethylangolensin, 4-
hydroxyphenyl-2-propionic acid, and 4-ethylphenol.
Besides the gut-derived genistein catabolites, unconju-
gated genistein is absorbed in the intestine and to a smaller
extent also in the colon [14–16]. A large part of the absorbed
genistein enters the portal vein in the form of glucuronides
and sulfates formed by phase II enzymes in the intestine and
colon. The remaining genistein that enters the portal vein
is metabolized by UDP-glucuronosyltransferases and sulfo-
transferases in the liver. The liver releases the genistein glu-
curonides and sulfates and they either go through the entero-
hepatic cycle or into the sinusoidal blood stream [17–20]. In
man only a few percent of unconjugated genistein will en-
ter the circulation [21], whereas in rodents this fraction can
be much higher [22]. Interestingly, it has been shown that
genistein glucuronides can be hydrolyzed back into genistein
aglycone by cellular enzymes, whereas sulfates cannot [16].
Some human studies comparing the absorption of pure
genistein with that of conjugated glycosides showed greater
bioavailability when ingested as beta-glycosides rather than as
aglycone, as measured from the area under the curve (AUC)
[23, 24], while one study showed identical bioavailability [25].
In all studies the elimination half-lifes (t1/2) and the mean
residence time of the total genistein were similar between
both aglycone and glycoside forms. Although differences in
absorption between the two forms were noted by Yuan et al.,
the Cmax and AUC0–24h values after glycoside or aglycone in-
take were not significantly different for all metabolites.
The phase II metabolites of genistein in human
plasma are glucuronidated and sulfated forms at po-
sitions 4′ and/or 7. The major conjugated metabolites
identified in human plasma were genistein-4′-sulfate-7-
glucuronide (G-4′S-7G), genistein-4′,7-diglucuronide (G-4′,7-
diG), genistein-7-sulfate (G-7S), genistein-4′-glucuronide (G-
4′G), genistein-7-glucuronide (G-7G), genistein-4′-sulfate
(G-4′S), and genistein-4′,7-disulfate (G-4′,7-diS), whereas G-
4′S and G-4′,7-diS were extremely low abundant [24, 26,
27]. Together with gut-derived metabolites dihydrogenis-
tein, 6′-hydroxy-O-desmethylangolensin, 4-hydroxyphenyl-
2-propionic acid, and 4-ethylphenol they represent the
metabolic fate of genistein in the ecosystem of the human
superorganism [28].
In this study, we aimed to explore the nutrikinetic pattern
of the metabolic fate of genistein conjugates and metabolites
as detected by highmass resolution HPLC-Orbitrap FTMS in
plasma from 12 healthy individuals, after oral consumption
of genistein tablets, genistein in low-fat milk or soy milk. For
this study, we employed the nutrikinetics concept [28,29] and
investigated the order of appearance of the different genistein
derivatives by using population-based modeling.
2 Materials and methods
2.1 Subjects, study design, and test formats
This study was a prospective, 3-periods cross-over, random-
ized, single-dose trial conducted at one study center (Galmed,
Halle, Germany). The study was conducted in an open, un-
blinded fashion, the treatment periods were separated by
a washout of at least 7 days. The study was conducted in
12 healthy Caucasian subjects (six male, six female, 18–
40 years, BMI 18–28, nonsmokers/smokers up to ten
cigarettes per day). Subjects that were participants in any
other study or donated blood during the last 30 days before
start, with known hypersensitivity or allergy to soy, peanuts,
purified isoflavones, genistein, lactose, and/or cow milk or
had preexisting chronic diseases or were taking drugs were
excluded. Soy-based foods or isoflavone supplements were
prohibited prior and during the study. The study was ap-
proved by the independent ethics committee of the General
Medical Council of Land Saxony-Anhalt and was conducted
according to the principles of the international conference
on harmonization of technical requirements for registra-
tion of pharmaceuticals for human use (IHC) good clinical
practice (GCP) according the declaration of Helsinki (ICH-
GCP). A signed informed consent was obtained from the
participants.
Pure genistein (min. 98.5% genistein, supplied by DSM
Nutritional Products, Switzerland) was granulated and com-
pressed into tablets and packaged by SwissCo, Switzerland
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under GMP requirements and control. Samples were re-
tained and stored at the sponsor′s site. According to a ran-
domization scheme the subjects (each treatment period, three
groups of n = 4) were administered a genistein tablet with
200 mL of tap water or a tablet with 500 mL low-fat cow
milk (referred to as “low-fat milk’) or 500 mL soy milk. All
three formats contained 30mg genistein, only in the soymilk
genistein was present as a glycoside (genistin). The subjects
were required to drink it within 5–10 min. The subjects were
housed in a clinical study test facility throughout the pharma-
cokinetic study in controlled setting that included standard-
ized meals at defined times for all subjects. Ten milliliters of
venous blood was drawn into an EDTA plasma-tube at each
sampling point. It was centrifuged with 1550 g (3000 rpm)
for 10 min at 4C to collect plasma. Blood sampling was at
the time points –12 and –0.5 h before and 0.5, 1, 1.5, 2, 3, 4,
5, 6, 8, 9, 10, 13, 16, 24, 36, 48 h after administration of the
single-dose treatment. Seven time points, –0.5, 3, 5, 9, 16, 24,
and 36 h, were included in the nutrikinetic study described
in this paper.
Safety and tolerability of the genistein tablets administered
as a single oral dose of 1 × 30 mg genistein with 12 healthy
subjects was good. No clinically relevant abnormalities were
observed in the medical examinations and in the laboratory
investigations. The studywas completedwithout any dropout.
Two adverse events were reported (headache and abdominal
pain in relation to menstruation) after administration of soy
milk. Any relation to the soy milk was not given. After intake
of the genistein tablets no adverse event was observed.
2.2 Reagents and chemicals
Methanol and acetonitrile (HPLC grade) were purchased
from BioSolve BV (Valkenswaard, the Netherlands), formic
acid (p.a. grade) from Merck (Darmstadt, Germany). Genis-
tein was purchased from Extrasynthese (Genay, France).
Genistein 4′-ß-D-glucuronide, genistein 7-ß-D-glucuronide,
and genistein 7-ß-D-glucuronide 4′-sulfate from Toronto Re-
search Chemicals (Ontario, Canada). Daidzein, phloroglu-
cinol (1,3,5 trihydroxybenzene), pyrogallol, 2(4-hydroxy
phenyl)-propionic acid, and gallic acid were purchased from
Sigma-Aldrich (St Louis, USA). The commercial human
plasma (from single donors aged between 18 and 65) used
as quality control (QC) was purchased from Innovative Re-
search (Michigan, USA – Cat#: IPLA-N).
2.3 Sample preparation and LCMS analysis
Plasma extracts were prepared as follows: 1.2 mL of extrac-
tion mix composed of 83.3% ACN, 1.3% v/v of formic acid
(FA) and 2.9 mM of vitamin C was added to 0.4 mL of plasma
sample. The sample was immediately vortexed and allowed to
rest for 20 min on ice and then sonicated for 15 min and cen-
trifuged for 10 min at 2500 rpm. The supernatant was firstly
partially dried in a speed-vac for 1 h, to remove excess of
ACN, and then completely dried overnight in a freeze dryer.
The residue was reconstituted in 100 L of 50% methanol
in 0.1% FA, briefly vortexed, allowed to stand on ice for
20 min, sonicated for 15 min and centrifuged again for
20min. The supernatant was filtered through a 0.45m inor-
ganic membrane filter and finally transferred into an HPLC
vial with glass inset.
The LC-MS system consisted of an Accela HPLC system
with an Accela photodiode array (PDA) detector connected
to a LTQ/Orbitrap FTMS hybrid mass spectrometer (Thermo
Fisher Scientific) equipped with an ESI source and controlled
by Xcalibur 2.1 software. The injection volume was 5 L
and LC separation was achieved on a Luna C18(2) analyti-
cal column (150 × 2 mm, 3 m particle size, Phenomenex,
Torrance, CA). The mobile phase A consisted of MQ water
and the mobile phase B of ACN, both acidified with 0.1% FA.
The flow rate was 0.19 mL/min, column and sample orga-
nizer were set up at 40C and 4C, respectively. The linear gra-
dient started at 5% and increased to 35% B in 45 min. Then,
15 minutes of washing and equilibration before next sample
injection was programmed, resulting in a total run time of
60 min.
The MS analysis was carried out in ESI-negative mode.
Data were collected at m/z 100−1000 with a resolution of
60.000 (at m/z 400) in centroid mode. The capillary tempera-
ture was 295C, sheath gas flow was set at 50 arbitrary units
(a.u.), auxiliary gas flow at 5 a.u. and the sweep gas flow at
5 a.u. TheOrbitrap was externally calibrated in negativemode
using sodium formate clusters in the rangem/z 150–1200 and
automatic tuning was performed on m/z 384.93. AGC target
value of the Ion Trap was set at 30 000 charges. The ion tube
was cleaned between each sample batch, in order to retain
sensitivity.
Samples were divided into 12 batches of 21 study samples,
each batch corresponding to all seven selected time points
of the three treatments per volunteer. Each injection batch
corresponded to these 21 study samples injected in a random
order plus three commercial plasma QCs samples analyzed
in the beginning, middle, and end of the sample series.
2.4 Data preprocessing
The identification of genistein, genistein conjugates,
daidzein, and phenolic compounds in the study samples was
based on corresponding accurate mass (within 2 ppm ac-
curacy) and retention times compared with the reference
compounds. For this purpose, the raw data files were all
preprocessed (peak picking by unbiased baseline correction
and noise estimation) using metAlign software [30]. Met-
Align output files (.redms_acc format) were used for ultra-
fast mass_retention time searching using the Search_LCMS
module within the MetAlign software. Output files were in
.csv format and contained accuratemass, retention time, scan
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Table 1. Metabolites included in the nutrikinetic analyses
No. Metabolite Group of metabolites
1 Free genistein Intact isoflavone
2 Genistein 4′-glucuronide
(G-4′G)
Phase II metabolite
3 Genistein 7-glucuronide
(G-7G)
Phase II metabolite
4 Genistein 4′-sulfate
(G-4′S)
Phase II metabolite
5 Genistein 7-sulfate
(G-7S)
Phase II metabolite
6 Genistein 4′-sulfate-7-
glucuronide
(G-4′S-7G)
Phase II metabolite
7 Genistein 4′-glucuronide-
7-sulfate
(G-4′G-7S)
Phase II metabolite
8 Genistein diglucuronide
(G-4′,7-diG)
Phase II metabolite
9 Dihydrogenistein Gut-mediated metabolite
10 Benzoic acid Gut-mediated metabolite
11 Phloroglucinol (1,3,5-
trihydroxybenzene)
Gut-mediated metabolite
12 Pyrogallol Gut-mediated metabolite
13 3-OH Benzoic acid Gut-mediated metabolite
14 2,4-Dihydroxy benzoic
acid
Gut-mediated metabolite
15 2(4-Hydroxy
phenyl)propionic acid
Gut-mediated metabolite
16 Gallic acid Gut-mediated metabolite
17 Hippuric acid Gut-mediated metabolite
18 2,6-Dimethoxy benzoic
acid
Gut-mediated metabolite
19 p-Cresol-sulfate Gut-mediated metabolite
20 Resorcinol sulfate Gut-mediated metabolite
21 4-Ethylphenol sulfate Gut-mediated metabolite
22 5-Hydroxy-equol Gut-mediated metabolite
23 5-(3,4-Dihydroxyphenyl)-
-valerolactone
Gut-mediated metabolite
number, ppm mass error, and signal intensity (peak height)
for each target compound in each sample.
Analytical variation like decreasing system sensitivity, col-
umn degradation, MS source pollution, sample degradation
etc. during the analysis of a batch of samples was monitored
by the inclusion of QC samples, i.e. samples that have a fixed
composition and analyzed at specified intervals within that
batch of samples [31]. These QC samples were placed at the
beginning, middle, and end of each analytical batch. It was
assumed that the same analytical variation was present in the
measurements of the QC and study samples.
2.5 Noncompartmental plasma kinetic analysis
Noncompartmental plasma kinetic analysis for each genis-
tein metabolite (Table 1) included evaluation of the maxi-
mum intensity levels (Imax), time to reach Imax (tmax), and
the area under the curve of metabolite intensity versus time
(AUC[0-t]). Imax and tmax were read directly from the observed
curves. AUC[0–t] was calculated according to the linear trape-
zoidal rule from0hour (intensity levelmeasured at t= –0.5 h)
to the last quantifiable intensity level after treatment adminis-
tration (intensity level measured at t = 36 h). Terminal elim-
ination half-time (t1/2) was calculated as (ln2)/kel = 0.693/kel,
where kel is the terminal rate constant calculated by least-
squares regression of the terminal semi-logarithmic intensi-
ties versus time data.
Descriptive statistics were calculated for Imax, tmax AUC[0–t],
and t1/2 on the basis of unchanged (tmax, t1/2) and log trans-
formed data (Imax and AUC[0–t]). They included mean ± SD.
Wilcoxon signed rank test for zero median (p < 0.05) was
used to assess differences between three different treatments.
False discovery rate (FDR) correction of obtained p-values by
Benjamini–Hochberg was applied with q = 0.05.
2.6 Selection of metabolites for population-based
nutrikinetic modeling
Metabolite intensity versus time-curves of all metabolites in-
cluded in the study were visually inspected (see Supporting
Information Fig. 1).Metabolites detected in at least three time
points in at least eight out of the 12 subjects and present in
all treatment groups, and with reasonable shapes of their in-
tensity versus time-curves were selected for further statistical
analysis. This selection process yielded five metabolites: G-
4′G,G-7G,G-7S,G-4′S-7G, andG-4′,7-diG.Data of volunteers
1, 2, and 4 were excluded from further nutrikinetic model-
ing, because the curves were very much deviating from other
subjects and from first-order absorption and elimination.
2.7 Population-based nutrikinetic modeling
A one-compartment kineticmodel with first-order absorption
and elimination (equation (1)) was used to describe the time
courses y(t) of the genistein phase II metabolites in plasma
(metabolites selected as described in a previous section) at
a given dose D [32]. This kinetic model had four parame-
ters: , lagtime; V, volume of distribution; ka, absorption rate
constant; kel, elimination rate constant.
E (y(t)) = D
V
ka
ka − kel
(
e−kel (t−) − e−ka (t−)) , t ≥ 
E (y(t)) = 0, t < 
(1)
The parameters were estimated in a population modeling
approach using nonlinear-mixed effects models using
Monolix 3.1 software applied in Matlab R2010b (MONOLIX,
3.1 User Guide, software.monolix.org; [33]). An individual
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parameter vectorpik = [ik kaik Vik kelik ] (subject index
i = 1 . . . N; treatment index k = 1, . . . K) is expressed as
log(pik) = + k + bi + cik (2)
where + k represents the fixed effect for treatment k,
bi ∼ N (0,) the random effect of subject i and cik ∼ (0,)
the random effect of subject i and treatment k. The random
effects are assumed to be mutually independent and the total
variance is thus decomposed into the between-subject vari-
ance, , and the within-subject variance,  [34]. A constant
additive error model is assumed for the residual error.
SDs of the population estimates, sdpk, were calculated from
leave one subject out jackknife estimates according to [35]:
sdpk =
√
N − 1
N
∑
i
(pk\i − pk)2 (3)
Where pk represents the population parameters[
k kak Vk kelk
]
for treatment k, pk\i is the popula-
tion estimate without subject i, and pk = 1N
∑
i pk\i .
3 Results
3.1 Genistein and gut-derived metabolites
The LC-LTQ-Orbitrap FTMS platform applied at high mass
resolution in full-scan ESI-negative mode enabled the detec-
tion of both genistein aglycone and 22 isoflavonoid-related
metabolites within a mass accuracy of 2 ppm and in most
cases with specific mass fragments and/or coelution with
authentic standards. See Table 1 for the list of compounds
used in the further data analyses, and see also Supporting
Information Table 1 for detailed LCMS information of all tar-
get compounds and their identification level according to the
Metabolomics Society Initiative [36].
During the analysis, in most batches we observed a clear
decrease in total intensity, which is the sumof allmass signals
in the chromatogram as determined by the data preprocess-
ing software of the threeQC samples during the analysis time
of a sample batch (see Supporting Information Fig. 2 shown
by red crosses). This indicated a gradual loss of analytical sen-
sitivity in time, due to contamination of the ion source by the
concentrated plasma extract. A large difference between the
average total intensity of the QC samples per batch was also
observed, indicating batch-dependent variation in extraction
and/or analytical sensitivity. To compensate for between and
within batch variation, a QC-based batch-wise correction of
peak intensities was successfully applied [37]. The batch cor-
rection factor applied was equal for all metabolites detected
in that specific batch. The QC-corrected metabolites intensi-
ties were further used to explore their nutrikinetic patterns
by noncompartmental analysis and population-based nutriki-
netic modeling.
Figure 1. Overview of tmax (A) and t1/2 (B) observed for 23 genis-
tein metabolites in 12 (11 for t1/2) subjects after three different
treatments: genistein tablet, genistein tablet with cow milk, and
soy milk. The numbering of the metabolites corresponds to the
numbering in Table 1. The values are color coded and grouped
by treatment. Similarly, Fig. 1B shows t1/2 values for the subjects
that were estimated only for six of the seven human phase II
metabolites of genistein (metabolites 2, 3, 5, 6, 7, and 8) because
only for these metabolites linear relationship between terminal
semi-logarithmic intensities and time could be obtained. Subject
no. 4 was excluded from the t1/2 analysis for the same reason.
3.2 Noncompartmental analysis
Noncompartmental analysis was composed of the evaluation
of the maximum intensity levels (Imax), time to reach Imax
(tmax), the area under the curve of metabolite intensity versus
time (AUC[0–t]) and terminal elimination half-time (t1/2). The
overview of tmax and t1/2 values for all metabolites and subjects
included in the study is given in Fig. 1. Results of Wilcoxon
signed rank test, performed to compare different treatments
for Imax, tmax, AUC, and t1/2, are presented in Table 2.
Analysis of Imax andAUC[0–t] has shown that somemetabo-
lites are present only for some subjects, e.g. dihydrogenistein
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Table 2. Wilcoxon signed rank test p-values for between treatments comparison of nutrikinetic parameters: Imax, tmax, AUC, and t1/2
determined for genistein and its metabolites during noncompartmental analysis
Metabolitea) Imaxb) tmax AUC t1/2
A–Bc) A–C B–C A–B A–C B–C A–B A–C B–C A–B A–C B–C
1 >0.05 >0.05 0.0068 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
2 >0.05 >0.05 0.0068 >0.05 >0.05 >0.05 >0.05 >0.05 0.0342 0.0049 0.0244 >0.05
3 >0.05 >0.05 0.0210 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
4 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 0.0425 0.0186 0.0322 >0.05
5 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
6 >0.05 0.0425 0.0005 >0.05 >0.05 >0.05 0.0122 >0.05 0.0010 0.0010 >0.05 >0.05
7 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
8 0.0010 >0.05 0.0005 0.0156 0.0156 0.0020 0.0005 >0.05 0.0010
9 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
10 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
11 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
12 >0.05 >0.05 >0.05 >0.05 0.012 >0.05 >0.05 >0.05 >0.05
13 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
14 0.0024 >0.05 >0.05 >0.05 >0.05 >0.05 0.0010 >0.05 >0.05
15 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
16 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
17 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
18 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
19 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
20 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
21 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
22 0.0313 >0.05 0.0313 0.0313 >0.05 0.0313 0.0313 >0.05 >0.05
23 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05
a) The numbering of the metabolites corresponds to the numbering given in Table 1.
b) Only p-values lower than 0.05 are given, p-values that indicate significant difference also after false discovery correction are indicated
in bold.
c) Treatments: A: genistein tablet; B: soy milk; C: genistein tablet with low-fat cow milk.
is present only for subject 9 and some metabolites are only
present after soy milk treatment: 3-hydroxy benzoic acid
and 5-hydroxy equol. Statistically significantly higher Imax in
soy milk treatment group were found for genistein, G-4′G,
G-7G, G-4′S-7G when compared with Imax of tablet with low-
fat milk group. This was also the case for G-4′,7-diG when
compared to both tablet and tabletwith low-fatmilk group and
for 2,4-dihydroxy benzoic acid when compared to the tablet
group. After FDR correction differences in genistein, G-4′G,
G-4′S-7G, G-4′,7-diG, and 2,4-dihydroxy benzoic acid were
still statistically valid. Statistically significant higher AUC[0–t]
in the soy milk treatment group were found for G-4′S-7G,
G-4′, 7-diG, and 2,4-dihydroxy benzoic acid when compared
with the tablet group and for G-4′G, G-4′S, G-4′S-7G, and
G-4′,7-diG when compared to the tablet with low-fat milk
group. After FDR correction differences in AUC[0–t] of G-4′S-
7G, G-4′,7-diG, and 2,4-dihydroxy benzoic acid were still sta-
tistically valid. However, no difference was observed between
genistein tablet and genistein tablet with low-fat milk. All in
all, the most significant differences were seen for phase II
metabolites. Unfortunately, for the gut-mediated metabolites
the interindividual variability was too high to perform such
noncompartmental data analysis.
The tmax of genistein and most human phase II metabo-
lites of genistein ranged between 3 and 9 h (Fig. 1A). In
contrast, tmax of gut-mediated metabolites of genistein varied
from t = 0 h to t = 36 h. We observed a large interindivid-
ual variation in tmax values, especially for the gut-mediated
metabolites. The tmax of G-4′,7-diG was statistically signifi-
cantly shorter in the soy milk treatment group when com-
pared with the tablet-with-milk group.
The t1/2 values for the subjects were estimated for six of the
seven human phase II metabolites of genistein (metabolites
2–3 and 5–8) because only for these metabolites a linear rela-
tionship between terminal semi-logarithmic intensities and
time could be obtained. For subject 4, there was no linear re-
lationship between terminal semi-logarithmic intensities and
time for none of the metabolites, and this subject was there-
fore excluded from the t1/2 analysis. Six phase II metabolites
of genistein differed in their t1/2 values (Fig. 1B), ranging
from 1 to 36 h. The t1/2 of the single-conjugated genistein
forms, either glucuronidated or sulfated, were shorter than
its double-conjugated forms, like glucuronide-sulfates and
diglucuronides. The t1/2 of G-4′G, G-4′S-7G, and G-4′,7-diG
were significantly shorter in the soy milk treatment group
when compared with tablet group, also after FDR correction.
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Table 3. Population estimates for , tpeak, and the sum of these (tmax) for five phase II metabolites
Metabolitea)  (h) SD  (h)
from jack-
knife
tpeak (h) SD tpeak (h)
from jack-
knife
tmax (h)b)
Genistein tablet
Genistein-4′,7 diglucuronide (G-4′,7-diG) 0.91 0.73 7.93 1.51 8.84
Genistein 7-sulfate (G-7S) 1.94 0.79 1.34 0.54 3.31
Genistein 4′-sulfate-7-glucuronide (G-4′S-7G) 2.53 0.27 3.38 1.08 5.91
Genistein 4′-glucuronide (G-4′G) 2.80 0.50 2.02 0.84 4.82
Genistein 7-glucuronide (G-7G) 3.07 0.44 1.44 0.56 4.51
Soy milk
Genistein 4′,7diglucuronide (G-4′,7-diG) 1.05 0.73 3.52 0.97 4.57
Genistein 7-sulfate (G-7S) 2.47 0.85 1.47 0.60 3.94
Genistein 4′-sulfate-7-glucuronide (G-4′S-7G) 2.64 0.32 3.40 1.01 6.04
Genistein 4′-glucuronide (G-4′G) 3.08 0.39 1.29 0.28 4.37
Genistein 7-glucuronide (G-7G) 3.58 0.34 0.66 0.25 4.23
Genistein tablet with low-fat cow milk
Genistein 4′,7 diglucuronide (G-4′,7-diG) 0.65 0.69 9.53 1.11 10.19
Genistein 7-sulfate (G-7S) 1.91 0.99 1.77 0.81 3.68
Genistein 4′-sulfate-7-glucuronide (G-4′S-7G) 2.13 0.38 5.23 1.57 7.36
Genistein 4′-glucuronide (G-4′G) 2.46 0.39 2.85 0.72 5.32
Genistein 7-glucuronide (G-7G) 3.09 0.61 1.87 0.86 4.96
a) They are listed in the appearance in the sinusoidal blood in all three treatments: genistein tablet; soy milk and genistein tablet with
low-fat cow milk.
b) , tpeak, and their sum tmax are explained in Fig. 2. The respective standard deviations (SD) from jackknife are listed. The detailed
calculations are available in the Supporting Information (Table 2).
3.3 Population-based modeling revealed order of
genistein phase II metabolites appearance
Fixed treatment effects, between-individual variance () and
within-individual () variance were calculated in Monolix,
with treatment as categorical variable. The treatment effect
for the genistein tablet treatment was set to 0, resulting in the
other treatments being expressed with respect to the genis-
tein tablet treatment. Since the treatments were intermitted
by washout periods no influence of treatment order was as-
sumed. Results of population-based modeling are presented
in Supporting Information Table 2 and include population
estimates of , lagtime; V, volume of distribution; ka, absorp-
tion rate constant; kel, elimination rate constant. The effect of
soy milk treatment on the volume of distribution (decreased
volume) was significant in G-4′G, G-7G, and G-4′G-7S. In
the jackknife models, the volume of distribution for these
metabolites is consistently lower for the soy treatment. The
soymilk treatment also had a significant effect on the absorp-
tion rate of G-4′,7-diG.
Table 3 provides time measures, which are explained in
Fig. 2. The time to reach maximum plasma concentration,
tmax, is the sum of , the lag between the administration of
the treatment and the appearance of the metabolite, and tpeak,
the time between the first appearance of the metabolite and
when it reaches maximum concentration. The calculated 
values in Table 3 represent their appearance of the metabo-
lites in the plasma. The lag time order was consistent in all
three treatments: G-4′,7-diG < G-7S < G-4′S-7G < G-4′G <
G-7G. The lag times after the soy milk treatment appeared
Figure 2. Explanation of the parameters , tpeak, and tmax used in
the calculation of values presented in Table 3.  is the time that
passes between the start of the experiment and the appearance
of a metabolite in the plasma and tpeak the time after  that it
takes to reach maximum intensity. The sum of the two, tmax, is
the equivalent of the noncompartmental tmax.
generally larger than after both tablet treatments, while tmax
were smaller.
We compared the population estimates for five phase II
metabolites with their group means from the noncompart-
mental analysis (see Supporting Information Table 3). The
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correlation coefficients for tmax, AUC, and Imax are all larger
than 0.9, although the means from the noncompartmental
analysis are generally lower than the population estimates.
For t1/2 the correlation coefficient is 0.89 (Supporting Infor-
mation Table 2) and the difference between the noncom-
partmental means and the population estimates is more pro-
nounced, with the noncompartmental estimates being larger.
In the noncompartmental analysis, kel is calculated in the
elimination phase, where ka is assumed to no longer influ-
ence the time profile. If the absorption in this phase is still
significant, kel is underestimated and t1/2 is estimated too
large. In the population analysis we used a one-compartment
bi-exponential model and the amount of absorption in the
elimination phase is taken into account in the estimation of
kel. This may result in more accurate estimates of absorp-
tion/elimination characteristics.
4 Discussion
Previous studies generally reported pharmacokinetic data
of isoflavones by estimating the phase II metabolites af-
ter measuring the free aglycones released by enzymatic hy-
drolysis (for review, [38]). In more recent studies [24, 26]
it was possible to assess metabolism and disposition of
isoflavone-conjugatedmetabolites in direct measurements of
the metabolites without hydrolysis. This was a major step to-
wards understanding the influence of the chemical form of
genistein on its disposition. Similar to these new reports [24,
26], our study confirmed G-7G-4′S and G-4′,7-diG to be the
major phase II conjugates, whereas unconjugated genistein
and genistein-4′-sulfate (G-4′S) were the least abundant. We
could not detect the proposed genistein-4′,7-disulfate (G-4′,7-
diS) [39] using the LC-LTQ-Orbitrap FTMS methodology. In-
terestingly, to the already known metabolites G-4′,7-diG, G-
4′S-7G, G-7G, G-4′G, G-7S, and G-4′S, we newly identified
G-4′G-7S in human plasma.
In order to enter the body the sugar moiety of the glu-
coside form of genistein needs to be cleaved by the micro-
biota by beta-glucosidases [5]. Currently, it is not clear what
drives the absorption efficiency of the aglycone. In the litera-
ture, conflicting results were reported. Higher bioavailability
of genistein provided as its glucoside was shown by some
groups [23,24], whereas others indicated greater bioavailabil-
ity of the aglycone [40,41] or noted no difference between the
absorption of the aglycone and that of the glucoside [25, 42].
In the present study, we observed a higher absorption of
soy milk genistin compared to genistein tablet independent
of the food matrix (water or low fat milk). The genistein
used in our study was an unformulated form, which pos-
sibly explains the lower bioavailability of the aglycone. Re-
sults from a separate study indicated that formulated genis-
tein has comparable bioavailability to the soy milk genistin
(unpublished results). Differences in formulation presum-
ably explain the lower bioavailability of the aglycone in this
study. Formulation of genistein seems therefore necessary
to achieve the optimal bioavailability for supplements or
foods.
The objective of our nutrikinetic analysis was to deter-
mine the order of appearance of the phase II metabolites of
genistein and the influence of food format on plasma disposi-
tion. We applied a metabolomics approach linked to nutriki-
netic modeling in a cross-over randomized clinical trial. Yet,
a number of human trials have been performed that define
pharmacokinetic properties of genistein [23, 25, 40, 42–44]
and its conjugates [24, 26, 27], but none of them applied nu-
trikinetics modeling for the purpose to define the order of
appearance of the respective metabolites in plasma. To our
knowledge the present study is the first that has successfully
applied this technology. We could show that in peripheral
blood, genistein supplementation independent of the food
matrices followed a defined pattern: G-4′,7-diG appeared first,
followed by G-7S, G-4′S-7G, and G-4′G, while the G-7G al-
ways was the last. This information is of interest, since it
demonstrates that phase II metabolism of genistein is highly
regulated. After passing the intestine and liver, genistein ap-
pears first in a di-glucuronidated form. It took more than one
hour for G-7S, and another half hour for G-7G-4′S, which is
one of the major genistein metabolites, to appear. The last
metabolite G-7G needed 2 hours longer than G-4′,7-diG to
become detectable in plasma. Yuan et al. [24] showed that
G-7G clearly is the most abundant phase II metabolite in
urine: the urinary excretion of G-7G was more than five
times higher than the second abundant phase II metabo-
lites (G-4′G and G-4′,7-diG) in urine. It remains to speculate
whether all the different genistein conjugates detected are
formed de novo in the intestine and/or liver after entero-
hepatic circulation of genistein aglycone in an initial step, or
whether the subsequent conjugates are formed in a second
step after the first appearing form, G-4′,7-diG, has been circu-
lated over the body tissues. Yang et al. [16] demonstrated that
within a tissue genistein glucuronides can be hydrolyzed back
into genistein aglycone. In fact, deglucuronidation by cellular
-glucuronidases seems to be a common mechanism for
many polyphenols [45]. If G-4′,7-diG is indeed firstly dis-
tributed into peripheral tissues where genistein aglycone can
be released by deglucuronidases, many possibilities remain
for the formation of newly conjugatedmetabolites.More than
19 isoforms of UDP-glucuronosyltransferases [45–47] and
more than 13 members of four sulfotransferases families
[48, 49] have been identified in humans, and these isoforms
have a broad and distinct tissue distribution.
Independent of the highly similar lag times () of G-4′,7-
diG appearance in plasma in all treatments, soy milk con-
sumption statistically significant shortened the tpeak of G-4′,7-
diG. This observation was statistically significant in both the
noncompartmental and the population-based models. The
genistein tablet in water or the genistein tablet in low fat
milk were both similar, but showed a delayed tpeak and tmax,
respectively, when compared to soy milk. We speculate that
the higher delay in case of tablet was due to the fact that
in these tablets the aglycone was unformulated and thereby
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less bioavailable. Alternatively, the genistein aglycone was ab-
sorbed for its largest part in the colon and not in the intestinal
compartments, or encountered an enhanced enterohepatic
circulation. The mechanism underlying the observed differ-
ence between tablet and soy milk in genistein nutrikinetics
remains to be further explored.
The postulated formation of 5-hydroxy-equol by gut bacte-
ria after genistein supplementation [9] could not be demon-
strated in our study, which is in line with recent observations
in plasma of gnotobiotic rats [7]. However, we were able to
detect 5-hydroxy-equol in plasma after soy milk treatment,
suggesting that this compound is a gut-derived metabolite
of daidzein rather than of genistein. To resolve the question
of whether 5-hydroxy-equol is produced from genistein by
human microbiota, we would need to apply labeled tracers
studies in healthy adults.
The two major gut-derived genistein metabolites, i.e. di-
hydrogenistein and 2(4-hydroxy phenyl)propionic acid, ap-
peared in the plasma according to the order of their forma-
tion [10–12]: dihydrogenistein reached tmax before 2(4-hydroxy
phenyl)propionic acid. However, the inter- and intraindivid-
ual variations were very high in all treatments. The AUC
of 2(4-hydroxy phenyl)propionic acid was ten times higher
compared to the AUC of dihydrogenistein. The 2(4-hydroxy
phenyl)propionic acid metabolite reached an AUC level com-
parably high to the major phase II metabolite and irrespec-
tive of the treatment, suggesting a functional enterohepatic
circulation linked to an active microbiota processing. Unfor-
tunately, for none of the gut-derived metabolites a terminal
elimination half-time could be calculated, due to the high
intra- and interindividual variability of the subjects. This high
variability of the gut-derived metabolites could not be obvi-
ated, although we applied a housed clinical setting that con-
trolled the timing, the amount, and the composition of the
supplied meals in all treatments. In future studies, further
stratification of subjects using other additional parameters
(e.g. microbiota composition, genetic background) might po-
tentially be helpful.
Novel methodologies in nutrikinetics that have been de-
veloped in the recent years allow to follow the metabolic fate
of nutrients using the metabolomics approach (reviewed in
[29]). The technology of nutrikinetic modeling for mechanis-
tic considerations of metabolite function requires a cross-
over design to reduce confounding sources of variation,
highly sensitive analytical instrumentation for simultaneous
metabolomics profiling, like in the present study, and a ded-
icated modeling strategy. This mathematical modeling ap-
proach will become instrumental for future dietary interven-
tions studies, where highly regulated homeostatic systems in
healthy individuals will be explored [50,51]. The present anal-
ysis nicely shows the potential of the nutrikinetics approach.
With its usewe could determine the order of appearance of the
phase II metabolites of genistein, an important nutraceutical
in human health. The nutrikinetics approach has of course its
limits, as it relies on the quality of the large data sets and the
underlying knowledge of the nutridynamic processes. To the
best of our knowledge, this is the first study that applied the
nutrikinetics approach for the soy isoflavone genistein.
In conclusion,weused ahighly sensitive LC-LTQ-Orbitrap
FTMS platform to detect genistein and its metabolites in
human plasma and developed a new nutrikinetic model to
determine the order of appearance of phase II metabolites.
Population-based nutrikinetic modeling is a powerful tool to
support the elucidation of themetabolic fate of phytonutrients
in human plasma. The current study showed that genistein
aglycone in water and in low-fat milk had highly similar nu-
trikinetic properties, i.e. no influence of the low-fat milk on
the systemic exposure of phase II genistein metabolites was
observed. Theperiods for the lag times () and for the tmax were
highly similar and the order of themetabolites was conserved.
We identified G-4′G-7S, a new phase II metabolite, in human
plasma. For all three application forms (genistein tablet in
water, genistein tablet in low-fat milk or soy milk genistin)
the plasma disposition of the metabolites was in the follow-
ing order: (1) G-4′,7-diG, (2) G-7S, (3) G-4′S-7G, (4) G-4′G,
(5) G-7G. Interestingly, after intake of the different genistein
or genistin formats, we observed G-7G-4′S and 2(4-hydroxy
phenyl)propionic acid to be themajor phase IImetabolite and
themajor gut-derivedmetabolite, respectively, for all formats.
The double glucuronidated metabolite G-4′,7-diG appeared
fastest (<1 h) whereas all mono sulfated, hetero-conjugated
and mono glucuronidated forms followed after a time lag of
>1 h. Themetabolic fate of the gut-derived genisteinmetabo-
lites showed high intra and interindividual variations, which
impeded population-based nutrikinetic modeling. Given the
fact that the bioavailable genistein firstly appeared as a dou-
ble glucuronidated conjugate (G-4′,7-diG) in plasma and the
subsequent genistein conjugates appear as mono- or hetero-
conjugated forms, we speculate that G-4′,7-diG is the pri-
mary genistein form, while the others may be derived from
secondary conjugations after tissue distribution and enzy-
matic hydrolysis of G-4′,7-diG. Future studies will need to
investigate which of the secondary conjugations are gener-
ated through enterohepatic recycling and which are taking
place in genistein target organs.
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